Aptose Common Shares to Delist from Nasdaq as of April 2, 2025
SAN DIEGO and TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX:APS),...
Cancer
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
Lab network revenue increased by 33% year over year, reflecting strong demand for ColoAlert® in Europe Operating loss decreased by...
Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress
CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering...
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit when combining CAN-2409 and nivolumab with standard of...
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
– Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture – REDWOOD CITY, Calif.,...
Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference
HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T...
Lantern Taps Industry Veteran for Labor, Union & Trust
Specialty Care leader looks to extend its success in commercial market by supporting growth in Union verticalDALLAS, April 01, 2025...
AZmed Receives Two New FDA Clearances for Its AI-Powered Chest X-ray Solution
PARIS, March 31, 2025 /PRNewswire/ -- AZmed, one of the leading AI companies in medical imaging, today announced that it...
Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update
Continues advancing clinical trial for INSTASYL siRNA lead product candidate PH-7623rd Cohort now fully enrolled in on-going clinical studyMarlborough, Massachusetts--(Newsfile...
GenomOncology Partners with Chronetyx Laboratories to Accelerate Cancer Care Through Comprehensive Genomic Profiling
CLEVELAND, March 31, 2025 /PRNewswire/ -- GenomOncology, a precision medicine software company, today announced a strategic partnership with Chronetyx Laboratories,...
Lunit Announces Partnership with the National Cancer Institute to Advance AI-Powered Biomarker Research
Collaboration to apply Lunit's AI technologies across NCI's broad spectrum of cancer studies, aiming to accelerate personalized cancer care SEOUL,...
IgniteData Advances Clinical Trial Efficiencies with Successful Deployment at Leading Cancer Center
NEW YORK, March 31, 2025 /PRNewswire/ -- IgniteData has announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK) and...
Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results
Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9...
LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100
Pre-Clinical Study in Collaboration with Netherlands Cancer Instituteis in addition to LIXTE’s Ongoing Clinical Trials for Ovarian and Colorectal Cancers...
Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025
SOLANA BEACH, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling...
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial
ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit...
Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing
Company executives will host a corporate webinar for investors and stakeholders on Thursday, April 10, 2025New York, New York--(Newsfile Corp....
Guo Guangchang’s Letter to Shareholders: Fosun International Pursues Progress through “Strategic Advancements and Exits”
HONG KONG, March 31, 2025 /PRNewswire/ -- Guo Guangchang, Chairman of Fosun International Limited (HKEX: 0656), issued a letter to...
Anthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding Risk
--Data presented at the American College of Cardiology Annual Scientific Session show that the reduction of bleeding with abelacimab compared...
Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates
SHANGHAI, March 28, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading...